Future of Specialty Pharmacy Highlights SPT Week in Review

5. Rituximab Biosimilar Demonstrates Comparable Safety, Efficacy to Reference Drug

CT-P10 is indicated to treat a form of non-Hodgkin lymphoma and rheumatoid arthritis.

https://www.specialtypharmacytimes.com/news/rituximab-biosimilar-demonstrates-comparable-safety-efficacy-to-reference-drug

4. How Has Opioid Use Changed Across the Rheumatoid Arthritis Landscape?

New analysis examines opioid use among patients with rheumatoid arthritis.

https://www.specialtypharmacytimes.com/news/how-has-opioid-use-changed-across-the-rheumatoid-arthritis-landscape

3. Rare Lymphoma: More Than Just an Internal Attack

The CEO of the Cutaneous Lymphoma Foundation describes the challenges of living with the disease.

https://www.specialtypharmacytimes.com/news/rare-lymphoma-more-than-just-an-internal-attack

2. New Strategic FDA Plan Seeks to Eliminate Orphan Drug Designation Request Backlogs

An estimated 200 orphan drug designation requests are pending FDA review.

https://www.specialtypharmacytimes.com/news/new-strategic-fda-plan-seeks-to-eliminate-orphan-drug-designation-request-backlogs

1. Will Specialty Pharmacies Be Needed in the Future?Drug development and innovation could render the current specialty pharmacy model obsolete in 20 years.

https://www.specialtypharmacytimes.com/news/will-specialty-pharmacies-be-needed-in-the-future